ISSN: 2332-0877

Journal des maladies infectieuses et de la thérapie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Cell Entry Inhibitor with Sulfonated Colloid Gold as New Potent Broad-Spectrum Virucides

Chur Chin

Nontoxic drugs that irreversibly inhibit viruses (virucidal) are postulated to be ideal on this pandemic era against respiratory viral spreading. Unfortunately, all virucidal molecules described to date are cytotoxic. We recently developed nontoxic, broad-spectrum virucidal gold nanoparticles, less than 10 nm sized modified with sulfonic acids (mesilate) to mimic heparan sulfates and to provide the key nontoxic virucidal action. The anti-influenza effects of Camostat, a serine protease inhibitor can introduce the gold nanoparticles to the influenza virus with ionic bonding. In this study, we have examined the ability of a novel sulfonated colloid gold to inhibit the influenza virus A/PR/8/34 (H1N1; PR8) strain of mice infection in vivo. Our data show that intranasal treatment of mice with A/PR/8/34 (H1N1;PR8) fully protected the animals from a lethal infection and significantly decreased the viral titers in the lungs of the infected animals. Thus, camostat-colloid gold is a promising candidate for the development of antiviral drugs for preventing and treating the influenza infection.